
Quarterly report 2025-Q3
added 11-06-2025
Haemonetics Corporation Revenue 2011-2026 | HAE
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Haemonetics Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.36 B | 1.31 B | 1.17 B | 993 M | 870 M | 988 M | 968 M | 904 M | 886 M | 909 M | 910 M | 938 M | 892 M | 728 M | 677 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.36 B | 677 M | 967 M |
Quarterly Revenue Haemonetics Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 327 M | 321 M | - | 349 M | 346 M | 336 M | - | 336 M | 318 M | 311 M | - | 305 M | 297 M | 261 M | - | - | 240 M | 468 M | 225 M | 240 M | 240 M | 209 M | 196 M | 259 M | 259 M | 253 M | 238 M | 247 M | 247 M | 242 M | 234 M | 234 M | 225 M | 211 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 468 M | 196 M | 275 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M | ||
|
Baxter International
BAX
|
2.75 B | $ 19.51 | 2.09 % | $ 9.95 B | ||
|
Becton, Dickinson and Company
BDX
|
21.8 B | $ 194.82 | 0.39 % | $ 56 B | ||
|
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | ||
|
Ekso Bionics Holdings
EKSO
|
17.9 M | $ 7.87 | -8.91 % | $ 159 M | ||
|
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | ||
|
Harvard Bioscience
HBIO
|
112 M | $ 0.66 | -1.73 % | $ 28 M | ||
|
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | ||
|
Repro Med Systems
KRMD
|
28.5 M | $ 5.64 | -3.01 % | $ 257 M | ||
|
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | ||
|
Alcon
ALC
|
9.91 B | $ 77.56 | -1.59 % | $ 40.4 B | ||
|
Merit Medical Systems
MMSI
|
1.36 B | $ 86.89 | -1.42 % | $ 5.06 B | ||
|
Nephros
NEPH
|
14.2 M | $ 4.88 | -0.03 % | $ 50.7 M | ||
|
AtriCure
ATRC
|
465 M | $ 39.21 | -0.88 % | $ 1.84 B | ||
|
ICU Medical
ICUI
|
2.38 B | $ 140.89 | -1.25 % | $ 3.44 B | ||
|
electroCore
ECOR
|
16 M | $ 4.48 | -0.11 % | $ 24.7 K | ||
|
iRhythm Technologies
IRTC
|
592 M | $ 176.72 | -0.41 % | $ 5.51 B | ||
|
AngioDynamics
ANGO
|
292 M | $ 12.68 | -1.25 % | $ 518 M | ||
|
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | ||
|
The Cooper Companies
COO
|
4.09 B | $ 81.36 | -0.74 % | $ 16.2 B | ||
|
Glaukos Corporation
GKOS
|
315 M | $ 111.38 | -1.36 % | $ 5.39 B | ||
|
LeMaitre Vascular
LMAT
|
220 M | $ 80.92 | -0.22 % | $ 1.82 B | ||
|
InfuSystem Holdings
INFU
|
110 M | $ 8.71 | -2.9 % | $ 180 M | ||
|
Masimo Corporation
MASI
|
2.09 B | $ 127.32 | -2.11 % | $ 6.79 B | ||
|
STERIS plc
STE
|
5.46 B | $ 250.01 | -1.38 % | $ 24.6 B | ||
|
Intuitive Surgical
ISRG
|
8.35 B | $ 559.18 | -1.27 % | $ 199 B | ||
|
OraSure Technologies
OSUR
|
186 M | $ 2.44 | 1.03 % | $ 182 M | ||
|
Microbot Medical
MBOT
|
117 K | $ 2.07 | 3.6 % | $ 21.1 M | ||
|
Utah Medical Products
UTMD
|
12.3 M | $ 56.55 | 1.06 % | $ 205 M | ||
|
Milestone Scientific
MLSS
|
8.63 M | $ 0.29 | 5.05 % | $ 23.1 M | ||
|
Stereotaxis
STXS
|
26.8 M | $ 2.31 | 0.43 % | $ 186 M | ||
|
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
2.51 B | $ 21.71 | - | $ 3.74 B | ||
|
DENTSPLY SIRONA
XRAY
|
3.79 B | $ 11.37 | -0.56 % | $ 2.31 B | ||
|
Pro-Dex
PDEX
|
66.6 M | $ 38.52 | 0.1 % | $ 127 M | ||
|
Predictive Oncology
POAI
|
1.62 M | - | - | $ 32.4 M | ||
|
Pulse Biosciences
PLSE
|
700 K | $ 13.42 | -2.26 % | $ 645 M | ||
|
ResMed
RMD
|
3.58 B | $ 243.75 | 1.2 % | $ 35.6 B | ||
|
Repligen Corporation
RGEN
|
632 M | $ 164.81 | 0.58 % | $ 9.18 M | ||
|
BioLife Solutions
BLFS
|
82.3 M | $ 24.22 | 0.14 % | $ 1.12 B | ||
|
Retractable Technologies
RVP
|
33 M | $ 0.77 | -0.7 % | $ 23.1 M | ||
|
STAAR Surgical Company
STAA
|
314 M | $ 23.57 | 2.08 % | $ 1.16 B | ||
|
Teleflex Incorporated
TFX
|
3.05 B | $ 121.96 | -0.1 % | $ 5.71 B | ||
|
West Pharmaceutical Services
WST
|
2.89 B | $ 275.24 | - | $ 20.1 B |